Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen (NASDAQ:AMGN) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Nov. 9, 2020, at 4:15 p.m. ET in Scottsdale, Ariz. Key executives, Murdo Gordon and Peter H. Griffith, will be representing the company. Investors can listen to the live audio on Amgen's website, with a replay available for 90 days. Founded in 1980, Amgen focuses on addressing unmet medical needs through innovative therapies and advanced human genetics. For more details, visit www.amgen.com.
Amgen reported Q3 2020 financial results with total revenues of $6.4 billion, up 12% year-over-year, driven by significant volume growth despite challenges due to COVID-19. Product sales also rose 12%, with notable increases in Otezla® and Repatha®. GAAP EPS increased 5% to $3.43, while non-GAAP EPS saw a 19% rise to $4.37. Free cash flow remained stable at $3.2 billion. Amgen narrowed its total revenue guidance for 2020 to $25.1-$25.5 billion and revised EPS guidance upwards.
Amgen (NASDAQ:AMGN) will release its third quarter financial results on October 28, 2020, after U.S. market close. Following this, a conference call will occur at 2:00 p.m. PT, featuring CEO Robert A. Bradway and senior management. The call will be accessible via live audio on Amgen's website, where it will also be archived for 90 days. Amgen continues to focus on innovative therapeutics, addressing high unmet medical needs, and has built a strong pipeline since its inception in 1980.
Amgen has completed discussions with the FDA regarding its Phase 2 trial for efavaleukin alfa, aimed at treating Systemic Lupus Erythematosus (SLE). This initiative is part of the FDA's Complex Innovative Trial Designs Pilot Program, focusing on modernizing drug development. The adaptive clinical trial design is expected to enhance the development of new therapies for SLE, addressing the significant unmet medical need in this area. The collaboration signals a commitment to improve efficiency and innovation in clinical trials.
Amgen (NASDAQ:AMGN) declared a $1.60 per share dividend for Q4 2020, payable on December 8, 2020, to shareholders recorded by November 16, 2020. This follows Amgen's commitment to improve health outcomes through innovative therapies, supported by a strong pipeline and advanced human genetics. The company, a pioneer in biotechnology since 1980, focuses on serious illnesses and has reached millions globally.
Amgen announced positive Phase 2 results for sotorasib, a KRAS G12C inhibitor, in treating advanced non-small cell lung cancer (NSCLC) in patients with prior treatment failures. The study involved 126 patients, showing an objective response rate consistent with past Phase 1 data and promising efficacy measures. More than half of responders remained on treatment at data cutoff. Amgen plans to discuss results with regulatory agencies and is advancing its development program, which includes a Phase 3 study, CodeBreaK 200, comparing sotorasib to docetaxel.
Amgen announced positive results for Aimovig (erenumab-aooe) at the Migraine Trust Virtual Symposium, showcasing a five-year study on its safety and efficacy in treating episodic migraine. The Phase 2 study involved 383 patients, with 216 completing the open-label phase. Results indicated a reduction of 5.3 monthly migraine days and 4.4 days less use of acute migraine medication. No increase in adverse events was recorded, affirming Aimovig's safety profile. This long-term data further establishes Aimovig as a leading preventive treatment for migraines.
Amgen announces updated data from the CodeBreaK 100 clinical study on sotorasib, a KRASG12C inhibitor, published in the New England Journal of Medicine. The study evaluated 129 patients across various advanced solid tumors. In 34 heavily pretreated patients with advanced non-small cell lung cancer (NSCLC), sotorasib showed an objective response rate of 35.3% and a disease control rate of 91.2%. Safety data demonstrated tolerability, with no dose-limiting toxicities. Upcoming Phase 2 results are highly anticipated among investors and the medical community.
Amgen will host two webcast investor calls during the ESMO 2020 Virtual Congress. The first call is scheduled for September 20, 2020, at 11:00 a.m. PDT, where Dr. David M. Reese will discuss Phase 1 data on the KRASG12C inhibitor, sotorasib (AMG 510). The second call is on September 21, at 1:00 p.m. PDT, focusing on a bispecific T-cell engager targeting PSMA. These webcasts will be available live and archived on Amgen's website for at least 90 days, making it accessible to investors and the public.
Amgen (NASDAQ:AMGN) announced it will present data from its oncology pipeline during the ESMO Virtual Congress 2020, taking place from Sept. 19-21, 2020. Key presentations include Phase 1 clinical results for AMG 510, a KRASG12C inhibitor for non-small cell lung cancer, and AMG 160, a bispecific T cell engager targeting prostate cancer. Highlights include a presentation on clinical benefit durability for AMG 510 on Sept. 20 and AMG 160 on Sept. 21. The company will also hold webcast calls on Sept. 20 and 21 to discuss Phase 1 data with investors.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
